Skip to main content
SVBI logo

SVBI — Investor Relations & Filings

Ticker · 1786 ISIN · TW0001786002 TW Manufacturing
Open in API
Filings indexed 1,687 across all filing types
Latest filing 2024-08-06 Director's Dealing
Country TW Taiwan
Listing TW 1786

About SVBI

www.scivision.com.tw

SciVision Biotech Inc. is a specialized developer and manufacturer of advanced medical devices, focusing on the research and production of hyaluronic acid (HA) products. The company leverages its proprietary Crosslinked Hyaluronic Acid Platform (CHAP) technology to create high-performance solutions across multiple medical disciplines. Its core product portfolio includes subcutaneous fillers for facial aesthetics, intra-articular injections for orthopedic joint care, anti-adhesion gels for surgical applications, and vesical instillation solutions for urological treatments. By integrating specialized R&D capabilities with precision manufacturing, SciVision Biotech provides medical-grade HA applications designed to improve patient outcomes in aesthetics and therapeutic recovery. The company is committed to scientific innovation and the expansion of its patented technology to meet diverse clinical needs in the global healthcare market.

Recent filings

Filing Released Lang Actions
113年07月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings and pledged shares by company insiders, including directors and senior management. It lists individual holdings, pledged shares, and related percentages. The content focuses on insider share transactions and holdings rather than financial results, management changes, or regulatory announcements. There is no indication of a report publication, voting results, or financial data. This matches the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives (insider trades). The document length is short (2484 characters), consistent with a typical insider shareholding disclosure rather than a full report. Therefore, the appropriate classification is Director's Dealing (DIRS).
2024-08-06 Chinese
112年年報及股東會資料 — 2023_1786_20240626FE6.pdf
Annual Report Classification · 100% confidence The document is titled 'SciVision Biotech Inc. 2023 Annual Report' and contains detailed sections typical of an annual report, including a report to shareholders, company profile, corporate governance report, fundraising, business overview, financial information with audited consolidated financial statements, and review and analysis of financial position and performance. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. It includes comprehensive financial data, management discussion, and audited financial statements for the fiscal year 2023. Therefore, this document fits the definition of an Annual Report (10-K). FY 2023
2024-08-05 Chinese
112年年報及股東會資料 — 2023_1786_20240626F11.pdf
Annual Report Classification · 100% confidence The document is titled as an "Annual Report" for the fiscal year 112 (in the Republic of China calendar, corresponding to 2023). It contains detailed sections typical of an annual report, including a shareholder report, company overview, corporate governance report, financial overview with audited financial statements, management discussion and analysis, and other comprehensive disclosures. The document length is substantial (15,000 characters), and it includes actual financial data and analysis, not just an announcement or summary. The presence of auditor information and detailed financial tables further confirms this is a full annual report. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-08-05 Chinese
112年年報及股東會資料 — 2024_1786_20240626F05.pdf
Annual Report Classification · 100% confidence The document contains detailed financial statements, including balance sheets, income statements, and cash flow statements for the fiscal year 112 (which corresponds to 2023 in the Gregorian calendar). It includes an auditor's report from Ernst & Young with an unqualified opinion, management discussion of financial results, earnings distribution, and shareholder meeting voting results. The document also includes the audit committee's report and detailed notes on accounting policies and key audit matters. The presence of comprehensive financial data, audit opinions, and management reports for a full fiscal year indicates this is a full Annual Report. The document is lengthy (15,000 characters) and contains the actual report, not just an announcement or certification. Therefore, the appropriate classification is Annual Report (10-K). FY 2023
2024-08-05 Chinese
112年年報及股東會資料 — 2024_1786_20240626F17.pdf
Major Shareholding Notification Classification · 95% confidence The document contains detailed information about the top ten shareholders, their shareholdings, and their relationships as defined by accounting standards. It focuses on share ownership and related party disclosures rather than financial results, management changes, or meeting materials. This type of information aligns with notifications about major shareholdings and related party relationships. Given the content and the nature of the data, the document fits best under the category of Major Shareholding Notification (MRQ). The document length is short and does not indicate it is an announcement of a report or a certification, so it is not RPA or RNS.
2024-08-05 Chinese
112年年報及股東會資料 — 2023_1786_20240626FE4.pdf
Annual Report Classification · 100% confidence The document is titled 'SciVision Biotech Inc. 2023 Annual Report' and contains detailed sections typical of an annual report, including a report to shareholders, company profile, corporate governance report, fundraising, business overview, financial information with audited financial statements, and review and analysis of financial position and performance. It includes comprehensive financial data, management discussion, and audited financial statements for the fiscal year 2023. The length of the document (15,000 characters) and the detailed content confirm it is the full annual report rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-08-05 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.